Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods Under Section 41

Overview

The Therapeutic Goods Act 1989, enacted by the Parliament of Australia, addresses issues concerning the regulation and control of therapeutic goods, ensuring they are safe, of high quality, and effective for their intended use. The Act establishes a framework for the approval, regulation, and monitoring of therapeutic goods, including medicines, medical devices, and blood products. The revocation of manufacturing licences, as seen in the 2019 Gazette publication, reflects the Therapeutic Goods Administration's commitment to maintaining stringent quality standards within the industry. The policy objective is to uphold public health and safety by removing manufacturers from the licensing framework when necessary, which is evidenced by the revocations of licences for Leo Pharma Southport Pty Ltd and Nestle Australia Ltd at the request of the manufacturers themselves.

Scope and Application

The Therapeutic Goods Act 1989, administered by the Therapeutic Goods Administration under the Department of Health, applies to entities involved in the manufacturing, supply, and advertising of therapeutic goods within Australia. The Act encompasses a broad range of products including medicines, medical devices, blood and blood components, tissues, and vaccines. It applies to any person or entity conducting activities related to therapeutic goods, which includes manufacturers, importers, sponsors, and suppliers. The Act’s jurisdiction extends across the Commonwealth of Australia, ensuring a uniform regulatory framework is applied nationally. Notably, the Act allows for certain exclusions and exemptions, particularly for small and medium enterprises under specified thresholds. Additionally, the application and enforcement of the Act can be extended or restricted through subordinate instruments, providing flexibility in regulation. This legislative framework is designed to protect public health by ensuring that therapeutic goods available in Australia meet quality, safety, and efficacy standards.

Key Provisions

The Therapeutic Goods Act 1989 provides a framework for regulating therapeutic goods in Australia. Section 41(1)(d) of the Act allows the Secretary to revoke a licence for the manufacture of therapeutic goods upon request from the manufacturer or for other reasons deemed appropriate. The revocation of a manufacturing licence signifies that the manufacturer is no longer authorised to produce therapeutic goods. In this instance, the Secretary has revoked the licence of Leo Pharma Southport Pty Ltd (Licence No. MI-09122005-LI-001054-11) located at 18 Olympic Circuit, Southport, QLD, 4215, and Nestle Australia Ltd (Licence No. MI-25102004-LI-000066-1) situated at 8 Steel Street, Blacktown, NSW, 2148, both at the request of the respective manufacturers. The revocation of a licence imposes significant obligations on the affected entities. These companies are no longer permitted to manufacture therapeutic goods within the scope of their revoked licences. They must cease all manufacturing activities related to the therapeutic goods covered by the revoked licences. Additionally, they are required to comply with any additional instructions or conditions set by the Therapeutic Goods Administration (TGA) regarding the cessation of manufacturing operations, including the proper disposal or transfer of any inventory or materials that fall under the scope of the revoked licences. Failure to comply with the revocation and subsequent obligations can lead to serious consequences. Under the Therapeutic Goods Act 1989, non-compliance with the revocation of a manufacturing licence can result in both civil and criminal penalties. Civil penalties may include fines, while criminal penalties can involve imprisonment. The exact penalties depend on the nature and severity of the breach. For example, knowingly manufacturing therapeutic goods after a licence has been revoked can lead to substantial fines and imprisonment, reflecting the seriousness of contravening the Act's provisions. The Therapeutic Goods Regulations 2008 further detail the specific penalties applicable to different types of breaches.